UBS Group
ACTU

UBS Group’s Actuate Therapeutics ACTU Stock Holding History

UBS Group’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.41K Buy
3,534
+1,583
+81% +$3.67K ﹤0.01% 8931
2026
Q1 		$5.35K Sell
1,951
-3,170
-62% -$13.1K ﹤0.01% 8800
2025
Q4 		$31.3K Sell
5,121
-3,806
-43% -$26.1K ﹤0.01% 7501
2025
Q3 		$59.7K Buy
8,927
+6,580
+280% +$47.7K ﹤0.01% 7440
2025
Q2 		$14.3K Buy
2,347
+368
+19% +$3.21K ﹤0.01% 8657
2025
Q1 		$13.4K Buy
1,979
+45
+2% +$361 ﹤0.01% 8463
2024
Q4 		$15.4K Buy
+1,934
New +$15.8K ﹤0.01% 8048

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

UBS Group's ACTU Position: Q2 2026 in Review

UBS Group increased its Actuate Therapeutics (ACTU) stake by 81% in Q2 2026, buying an estimated $3.67K and bringing the position to 3,534 shares worth $5.41K. The position accounts for ﹤0.01% of the portfolio, ranked #8931.

UBS Group first reported a position in ACTU in Q4 2024 and has held it in 7 quarters since. The position peaked at $59.7K in Q3 2025. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • UBS Group held 3,534 shares of Actuate Therapeutics worth $5.41K as of Q2 2026.
  • UBS Group bought 1,583 Actuate Therapeutics shares in Q2 2026, an estimated $3.67K.
  • Actuate Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8931 holding.
  • UBS Group first reported a position in Actuate Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • UBS Group's Actuate Therapeutics position peaked at $59.7K in Q3 2025.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.